These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8181028)

  • 1. Role of vasodilator therapy in congestive heart failure. Effects on mortality.
    Greenberg B
    Cardiol Clin; 1994 Feb; 12(1):87-99. PubMed ID: 8181028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of ACE inhibitors in heart failure (clinical aspects)].
    Riegger AJ
    Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
    Dessì-Fulgheri P; Paci MV; Rappelli A
    Ann Ital Med Int; 1994 Oct; 9 Suppl():16S-18S. PubMed ID: 7857751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Ghose JC; Chakraborty S; Mondal M; Bhandari B
    J Assoc Physicians India; 1993 May; 41(5):269-71. PubMed ID: 8300456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in mortality by pharmacological therapy in congestive heart failure.
    Swedberg K
    Circulation; 1993 May; 87(5 Suppl):IV126-9. PubMed ID: 8485828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
    Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH
    Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
    Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI1-4. PubMed ID: 8500232
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cardiac failure and nitrates].
    Galinier M; Bounhoure JP
    Ann Cardiol Angeiol (Paris); 1997; 46(7):415-9. PubMed ID: 9452775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
    Paul SD; Kuntz KM; Eagle KA; Weinstein MC
    Arch Intern Med; 1994 May; 154(10):1143-9. PubMed ID: 8185426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic determinants of survival in congestive heart failure. The survival hypothesis: how small uncontrolled studies should influence the design of large-scale clinical trials.
    Francis GS
    Circulation; 1987 May; 75(5 Pt 2):IV74-9. PubMed ID: 3568319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P; Ziesche S; Johnson G; Cohn JN
    J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vasodilator agents: the lesson from large clinical trials].
    Galiè N; Magelli C; Rapezzi C; Branzi A; Magnani B
    Cardiologia; 1993 Dec; 38(12 Suppl 1):221-6. PubMed ID: 8020020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
    Mahgoub AA; El-Medany AH; Abdulatif AS
    Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in congestive heart failure: have we made a difference?
    Firth BG; Yancy CW
    Am J Med; 1990 Jan; 88(1N):3N-8N. PubMed ID: 2195883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.